Article

Cellular miR-6741-5p as a Prognostic Biomarker Predicting Length of Hospital Stay among COVID-19 Patients

Shaw M. Akula 1,2,*, John F. Williams 1, Lok R. Pokhrel 3, Anais N. Bauer 1, Smit Rajput 2 and Paul P. Cook 2

1 Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
2 Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA
3 Department of Public Health, Brody School of Medicine, East Carolina University, Greenville, NC 27834, USA

* Correspondence: akulas@ecu.edu

Abstract: Wide variability exists with host response to SARS-CoV-2 infection among individuals. Circulatory micro RNAs (miRNAs) are being recognized as promising biomarkers for complex traits, including viral pathogenesis. We hypothesized that circulatory miRNAs at 48 h post hospitalization may predict the length of stay (LOS) and prognosis of COVID-19 patients. Plasma miRNA levels were compared between three groups: (i) healthy volunteers (C); (ii) COVID-19 patients treated with remdesivir (an antiviral) plus dexamethasone (a glucocorticoid) (with or without baricitinib, a Janus kinase inhibitor) on the day of hospitalization (I); and COVID-19 patients at 48 h post treatment (T). Results showed that circulatory miR-6741-5p expression levels were significantly different between groups C and I (p < 0.0000001); I and T (p < 0.0000001); and C and T (p = 0.001). Our ANOVA model estimated that all patients with less than 12.42 Log2 CPM had a short LOS, or a good prognosis, whereas all patients with over 12.42 Log2 CPM had a long LOS, or a poor prognosis. In sum, we show that circulatory miR-6741-5p may serve as a prognostic biomarker effectively predicting mortality risk and LOS of hospitalized COVID-19 patients.

Keywords: SARS-CoV-2; miRNA; biomarker; COVID-19; LOS

1. Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes Coronavirus Disease 2019 (COVID-19) [1]. As of 2 September 2022, over 604 million cases of COVID-19 have been documented, with death toll surpassing 6.5 million globally (WHO report). The health and economic toll of COVID-19 will increase over time. Further, the emergence and spread of SARS-CoV-2 variant of concern (VOC) have raised questions about the efficacy of current vaccines and monoclonal antibody therapies [2].

Early manifestations of SARS-CoV-2 infection are protean, but ageusia and anosmia are common [3]. Other common symptoms include fever, cough, dyspnea, myalgias and/or fatigue [4]. In severe cases, there may be acute respiratory distress syndrome (ARDS) or even multi-organ failure [5]. There are increasing reports of some survivors suffering Long COVID [6], a chronic illness with ongoing multidimensional symptomatology and disability that may last for weeks to years after the initial infection [7]. The most common symptom associated with Long COVID is asthenia [8,9]. The other general symptoms that may be associated with Long COVID are fever, chills, anorexia, and general malaise [10]. Long COVID may affect multiple organs in the cardiovascular [11], respiratory [12], nervous [13], digestive [14], urinary [15], and the reproductive systems [16]; and thus may result in a varied tissue-specific clinical manifestations.

MicroRNAs (miRNAs) are small non-coding RNAs (ncRNA), 19–25 nucleotides in length, derived from hairpin shaped precursor molecules encoded by the genomes of animals, plants, and viruses [17]. miRNAs control gene expression and regulate a wide
array of biological processes by targeting messenger RNAs (mRNA) and inducing translational repression or accelerated RNA degradation [18]. The miRNA expression profiles are tissue-/cell-specific [19]. In recent years, miRNAs have been studied as likely candidates involved in most biologic processes; they have been implicated in many human diseases, including COVID-19 [20]. The circulatory miRNAs present in blood are enclosed in vesicles (exosomes), which protect them from degradation [21]. The stability of miRNAs in blood, their tissue specificity, and the ease with which they can be quantified make them a viable alternate to serve as a clinical biomarker for a wide range of diseases. We hypothesized that the dynamic changes in the circulatory miRNAs could reflect the severity of COVID-19 and thereby better predict length of hospital stay (LOS) and mortality risk. Our study demonstrates that miR-6741-5p plasma levels could predict LOS of hospital admitted patients by 48 h with high confidence and mortality risk. The study further describes the significance of miR-6741-5p in the biology of COVID-19.

Treating COVID-19 and associated respiratory illness can be a major strain on the healthcare and economic systems. Pandemics may result in a sudden increase in demand for inpatient facilities with a corresponding increase in the number of infected cases [22]. Liquid biomarkers such as miR-6741-5p have the advantage of real-time, non-invasive longitudinal monitoring of a disease condition and heterogeneity over tissue markers [23]. This is the first study that describes a miRNA with potential to serve as a prognostic biomarker for predicting LOS and mortality risk. Predicting factors (such as circulating miR-6741-5p) associated with the LOS can not only aid in triaging patients in a timely manner but also assist in efficiently treating patients and managing hospitals.

2. Materials and Methods

2.1. Human Participants and Samples

This was a single-center study. The patient plasma samples were obtained from the Department of Pathology, Vidant Medical Center, Greenville, NC. These specimens were from COVID-19 positive patients with moderate-severe disease. The patient details and the demographics are provided in Tables 1 and 2, respectively. The inclusion criteria for the COVID-19 participants were, (i) age ≥ 18 years; (ii) hospitalized ≤ 48 h; (iii) confirmed SARS-CoV-2 by PCR; and (iv) moderate-severe pneumonia as assessed by radiographic imaging and oxygen requirements. All subjects were requiring supplemental oxygen at the time of the blood sampling. Plasma from healthy volunteers were used as controls. The healthy volunteers were apparently healthy people who did not exhibit symptoms of COVID-19 or any other form of respiratory distress in the past 14 days. None of them were vaccinated for COVID-19 as it was not available at that time. We age-matched the healthy controls by choosing healthy volunteers aged between 30 and 66 years of age. Plasma samples were collected from the hospitalized participants at two different time points: on the day of admission (treated with an antiviral plus 6 mg of dexamethasone administered orally) and 48 h post treatment. Treatment of COVID-19 patients involved an antiviral, remdesivir and dexamethasone (a glucocorticoid). Six of the eighteen subjects received baricitinib, an oral Janus kinase inhibitor with potent anti-inflammatory effects, in addition to dexamethasone. Different antivirals were used, which are listed in Table 1. A one-time blood draw from healthy volunteers provided plasma samples that were used as controls in this study.

2.2. Study Design and Approval

COVID-19 positive human plasma samples were obtained from the department of Pathology, East Carolina University. Control plasma samples were obtained from healthy participants with informed written consent before inclusion in the study in accordance with Declaration of Helsinki principles. All protocols were approved by the University and Medical Center IRB (UMCIRB) review board (approved UMCIRB study number is UMCIRB 20-001604).
Table 1. Our predictions based on expression values for miR-6741-5p.

| Patient ID | Age | Treatment Received          | Co-Morbidities                   | Day 0 | Day 02 | Prediction-Based on CPM Values | LOS                     |
|------------|-----|------------------------------|----------------------------------|-------|-------|-------------------------------|-------------------------|
| A          | 75  | Remdesivir + dexamethasone   | HTN, paraplegia                 | 9.5   | 11.5  | ✓                             | Discharged on day 4     |
| B          | 73  | Remdesivir + dexamethasone   | HTN, DM, obesity               | 10.4  | 11.5  | ✓                             | Discharged on day 4     |
| C          | 68  | Remdesivir + dexamethasone   | HTN, asthma, DM, obesity        | 8.9   | 10.7  | ✓                             | Discharged on day 5     |
| D          | 77  | Remdesivir + dexamethasone   | DM                               | 11.4  | 13.2  | X                             | Dead on day 16          |
| E          | 49  | Remdesivir + dexamethasone   | Renal transplant, HTN, DM       | 11.0  | 13.4  | X                             | Discharged alive; died 3 days later |
| F          | 71  | Remdesivir + dexamethasone   | HTN, DM, prostate cancer        | 12.1  | 13.8  | X                             | Discharged on day 23    |
| G          | 56  | Remdesivir + dexamethasone   | ESRD, HTN, DM                   | 8.2   | 9.9   | ✓                             | Discharged on day 12    |
| H          | 73  | Remdesivir + dexamethasone   | HTN, COPD                       | 11.2  | 13.4  | X                             | Dead on day 9           |
| I          | 45  | Remdesivir + dexamethasone   | DM, obesity                     | 8.5   | 10.2  | ✓                             | Discharged on day 5     |
| J          | 72  | Remdesivir + dexamethasone   | HTN, COPD, paraplegia          | 9.7   | 12.2  | X                             | Dead on day 15          |
| K          | 77  | Remdesivir + dexamethasone   | HTN, CHF, cirrhosis            | 8.6   | 12.6  | X                             | Dead on day 8           |
| L          | 67  | Remdesivir + dexamethasone   | HTN, DM, obesity               | 11.2  | 12.9  | X                             | Dead on day 26          |
| M          | 66  | Dexamethasone + baricitinib  | HTN                              | 11.0  | 11.3  | ✓                             | Discharged on day 6     |
| N          | 66  | Dexamethasone + baricitinib  | DM, obesity, sickle cell trait  | 13.2  | 13.8  | X                             | Discharged on day 57    |
| O          | 68  | Dexamethasone + baricitinib  | HTN, DM, obesity                | 13.0  | 15.3  | X                             | Died on day 16          |
| P          | 75  | Dexamethasone + baricitinib  | No comorbid conditions          | 12.0  | 12.8  | X                             | Discharged on day 15    |
| Q          | 57  | Dexamethasone + baricitinib  | HTN, DM, obesity               | 13.1  | 14.8  | X                             | Discharged on day 21    |
| R          | 64  | Dexamethasone + baricitinib  | CHF, CAD                        | 9.0   | 10.1  | ✓                             | Discharged on day 5     |

LEGEND: ✓ Prognosis is good; X Prognosis is bad; CPM denotes count per million.

2.3. Whole Transcriptome Assay

We determined the circulating miRNA profile in the human plasma specimens by performing the HTG EdgeSeq miRNA Whole Transcriptome Assay (miRNA WTA) (HTG Molecular Diagnostics, Inc. Tucson, AZ, USA). The HTG EdgeSeq miRNA WTA enables us to measure the expression of 2083 human miRNA transcripts using next-generation sequencing (NGS). The miRNA expression profile was determined in 20 μL of plasma samples as described previously in our earlier studies [24]. Batch effects are technical variations between the measurements due to factors, such as sample or reagent batches. We
limited the batch effects using the following checklist while performing NGS: samples were randomized in a balanced manner; samples were always used in duplicates; correlation of all sample pairs was confirmed; normalization was performed to transform the data in such a way as to make the data from different replicates and experimental conditions directly comparable; and a multivariate method of analysis (principal component analysis-PCA) performed to detect any possible batch effects. PCA was performed based on the Scree plot (eigen values vs. components).

Table 2. Sample information.

| Parameters                  | COVID-19 Patients (n = 12) | Healthy Volunteers (n = 8) |
|-----------------------------|-----------------------------|-----------------------------|
| Age, y, mean (SD)           | 66.6 (18)                   | 46 (7.3)                    |
| Sex, n (%)                  |                             |                             |
| Male                        | 8 (44.4%)                   | 3 (37.5%)                   |
| Female                      | 10 (55.5%)                  | 5 (62.5%)                   |
| Sample collected            | Blood (plasma)              | Blood (plasma)              |

2.4. Dual-Luciferase Reporter Assay

The 3′-UTR (with wild-type and mutant binding sites for miR-6741-5p) of HNRNPA1L2 (accession number: NM_001011724), and APOBEC3H (accession number: FJ376617), respectively, was PCR amplified and then cloned into XhoI/XbaI site located at 3′UTR of pmirGLO dual-luciferase vector (Promega, Madison, WI, USA). The 3′-UTR of HNRNPA1L2 and APOBEC3H with mutations to binding sites (MUT1 and 2) were generated by site-directed mutagenesis as per standard protocols [24]. HEK-293T cells were plated onto 6-well plates. At 24 h post-plating, HEK-293T cells were co-transfected with HNRNPA1L2 (or APOBEC3H) 3′-UTR luciferase reporter plasmid and miR-6741-5p mimic (or control mimic) using FuGene HD (Promega). At 48 h post transfection, the Renilla luciferase activity was measured using the dual luciferase reporter assay system (Promega) as per manufacturer’s recommendations. The oligos tested in this study are provided in Table S1.

2.5. Prognosis Evaluation

We performed One-way analysis of variance (ANOVA) to predict good or poor prognosis based on the log2 CPM values for the COVID-19 patients treated with remdesivir and dexamethasone (with or without baricitinib) on the day of hospital admission based on the circulatory miR-6741-5p expression levels (I group), and statistical comparisons were made between the healthy volunteers (C group) vs. I group, I group vs. T group (COVID-19 patients at 48 h post treatment), and C group vs. T group, using Tukey HSD post-hoc test. Our ANOVA model and parameter estimates for the three groups of patients are presented in Table 3, and Table 4 shows the ANOVA model and parameter estimates for predicting good or poor prognosis in COVID-19 patients treated with remdesivir and dexamethasone (with or without baricitinib) on the day of hospital admission based on the circulatory miR-6741-5p expression levels. Parameters were estimated with robust standard errors using HC3 method. Accordingly, the ANOVA model (Table 4) explaining good or poor prognosis is represented by Equation (1).

\[
\text{Good or poor prognosis} = \beta \times \log2 \text{ CPM} + \varepsilon_i
\]  

where \( \beta \) denotes coefficient, and \( \varepsilon_i \) denotes standard error representing any variance unaccounted for by the model. Based on our ANOVA model (Table 4), we then determined the estimated marginal mean for log2 CPM, which may serve as a “clinical threshold” between survival and death among COVID-19 patients that received the treatment on the day of hospital admission. We then compared the model predicted prognosis (survival or death) with the LOS and presented in Table 1.
Table 3. Results of Univariate Analysis of Variance (ANOVA) among the three groups of patients and parameter estimates using robust standard errors (HC3 method). The coefficient of determination (R squared) of the model was 0.988, suggestive of good model fit with sufficient predictive power.

| Source         | Type III Sum of Squares | df | Mean Square | F            | Sig.         |
|----------------|-------------------------|----|-------------|--------------|--------------|
| Model          | 19,528.148 a            | 3  | 6509.383    | 3593.522     | 7.96 × 10^{-122} |
| Group          | 19,528.148              | 3  | 6509.383    | 3593.522     | 7.96 × 10^{-122} |
| Error          | 228.239                 | 126| 1.811       |              |              |
| Total          | 19,756.387              | 129|             |              |              |

Tests of Between-Subjects Effects

Dependent Variable: Log<sub>2</sub> CPM

| Parameter                        | B         | Robust Std. Error | t         | Sig.         | 95% Confidence Interval |
|----------------------------------|-----------|-------------------|-----------|--------------|-------------------------|
|                                  |           |                   |           |              | Lower Bound | Upper Bound |
| Control (C)                      | 13.733    | 0.129             | 106.593   | 2.40 × 10^{-125} | 13.478     | 13.988     |
| Infected (I)                     | 10.936    | 0.214             | 51.009    | 5.33 × 10^{-86} | 10.512     | 11.361     |
| Infected + Treated (T)           | 12.839    | 0.193             | 66.556    | 4.91 × 10^{-100} | 12.457     | 13.221     |

* R Squared = 0.988 (Adjusted R Squared = 0.988); Computed using alpha = 0.05.

Table 4. Results of Univariate Analysis of Variance (ANOVA) among patients infected with SARS-CoV-2 that received dexamethasone treatment for 48 h (with good and poor prognosis). The coefficient of determination (R squared) of the model was 0.997, suggestive of good model fit with sufficient predictive power.

| Source         | Type III Sum of Squares | df | Mean Square | F               | Sig.         | 95% Confidence Interval |
|----------------|-------------------------|----|-------------|-----------------|--------------|-------------------------|
|                |                         |    |             |                 |              | Lower Bound | Upper Bound |
| Model          | 8977.149                | 2  | 4488.575    | 8020.432        | 1.75 × 10^{-65} |              |             |
| Good prognosis | 8977.149                | 2  | 4488.575    | 8020.432        | 1.75 × 10^{-65} |              |             |
| Error          | 29.101                  | 52 | 0.560       |                 |              |             |             |
| Total          | 9006.251                | 54 |             |                 |              |             |             |

| Parameter                        | B         | Robust Std. Error | t         | Sig.         | 95% Confidence Interval |
|----------------------------------|-----------|-------------------|-----------|--------------|-------------------------|
|                                  |           |                   |           |              | Lower Bound | Upper Bound |
| Poor prognosis                   | 13.675    | 0.130             | 104.989   | 3.20         | 13.414     | 13.936     |
| Good prognosis                   | 11.168    | 0.170             | 65.825    | 9.21 × 10^{-52} | 10.827     | 11.508     |

R Squared = 0.997 (Adjusted R Squared = 0.997); Computed using alpha = 0.05.

2.6. Statistics

The data satisfied normality (K-S test, p > 0.1); they were used untransformed unless stated otherwise. One-way analysis of variance (ANOVA) was performed to determine the statistical significance. ANOVA was performed using IBM SPSS v26 (Cary, NC, USA) to determine significant differences between the treatment and control groups, followed by Tukey HSD post-hoc test for multiple comparisons. The p-value was established at the 0.05 level.

3. Results

3.1. Differential Expression of Circulating miRNAs in COVID-19 Patients Treated with Dexamethasone

The clinical details of all patients are summarized in Table 1. By using the extraction-free HTG EdgeSeq system and bioinformatical analyses, the expression of 2083 circulating miRNAs were analyzed in the plasma derived from COVID-19 patients when compared...
to apparently healthy participants. The three comparisons were between the following groups: (i) Plasma from COVID-19 patients treated with remdesivir plus dexamethasone (with or without baricitinib) on the day of their admission to hospital (group I) versus plasma from healthy volunteers (group C); (ii) Group I versus plasma from COVID-19 patients obtained 48 h post treatment (group T); and Group C versus group T. Plasma samples for group I was collected before treatment on the day of admission.

Principal component analysis (PCA) shows that the miRNA expression profiles in group I and group C; group I and group T; and group C and group T segregated into distinct clusters along principal component 1 and principal component 2, explaining 77.4% and 10%; 84.6% and 5.6%; and 78.8% and 8.3% of the total variances, respectively (Figure 1A–C). The scree plots are provided in Figure S1 which depict principal components and their eigenvalues. To identify miRNAs that were significantly differently expressed between the two groups, volcano plot filtering was performed (Figure 1D–F). The focus of this study was to analyze the differences in the miRNA profiles within groups I and T. The number of differentially expressed miRNAs between groups I and T are relatively less when compared to groups I and C, and groups T and C (Figure 1D–F). The changes in miRNA profile between groups I and C were recently published [24].

**Figure 1.** Differentially expressed (DE) miRNAs in COVID-19 patients with moderate-severe disease (I) compared to treated (T) and healthy participants (C). (A–C) Principal component analysis (PCA) plot showing transcriptome differences between miRNA expression in I, T, and C group of COVID-19 patients. Each dot represents one of the total number of samples (12 samples from I and T group of COVID-19 patients and 8 samples from healthy participants) used in the sequencing-based screening. (D,E) Volcano plot for differentially expressed miRNAs, showing distribution of significance [−log10(p-value)] vs. fold change [log2(fold change)] for all genes. The red and blue dots represent downregulated and upregulated miRNA expression in I vs. C groups (D); I vs. T groups (E); and T vs. C groups (F), respectively. C denotes healthy volunteers, I denotes COVID-19 patients treated with remdesivir (an antiviral) plus dexamethasone (with or without baricitinib, a Janus kinase inhibitor) on the day of hospitalization, and T denotes COVID-19 patients at 48 h post treatment. The number of DE miRNAs is listed in the table provided under panels D, E, and F. Arrows denote specific miRNAs.
A total of nine miRNA levels were altered in a span of 48 h post dexamethasone treatment (Figures 1E and 2). Eight miRNAs were downregulated (Figure S2) while only one miRNA was upregulated in dexamethasone treated COVID-19 infected and hospitalized patients. The upregulated and dexamethasone treatment-induced miRNA was miR-6741-5p (Figure 2A). We focused the rest of our study on miR-6741-5p primarily owing to its dynamic expression pattern.

Figure 2. Differential expression of miR-6741-5p. (A) Box plot showing variation in miR-6741-5p expression (log2 CPM) among different patient groups: healthy volunteers (C), patients with COVID-19 (I), and patients with COVID-19 that received antiviral plus dexamethasone treatment (T). ‘**’ denotes significant difference between the means at \( p = 0.001 \); and ‘***’ denotes significant difference between the means at \( p < 0.0000001 \). Statistical significance was established at 0.05 level using ANOVA followed by Dunnett T3 post-hoc test. (B) Box plot showing variation in miR-6741-5p expression (log2 CPM) among the patients with COVID-19 that received treatment and either survived or died. ‘****’ denotes significant difference between the means at \( p = 4.68 \times 10^{-16} \) using ANOVA. The horizontal dotted line denotes estimated marginal mean of 12.42, which may serve as a “clinical threshold” between survival and death.

3.2. miR-6741-5p May Serve as a Predictor of Poor Prognosis

The circulatory miR-6741-5p expression was significantly lower in COVID-19 patients (I) compared to healthy volunteers (C) (Figure 2A). COVID-19 patients treated with remdesivir plus dexamethasone (with or without baricitinib) showed a dramatic increase in miR-6741-5p levels (Figure 2A). The miR-6741-5p expression in plasma obtained from patients treated with remdesivir plus dexamethasone (with baricitinib) at 48 h post treatment was slightly higher than those treated without baricitinib (12.82 vs. 10.3 log2 counts per million (CPM)). Plasma miR-6741-5p expression levels among the three groups of patients are shown in Figure 2. ANOVA results showed that circulatory miR-6741-5p expression levels were significantly different: (i) between the healthy volunteers (C) and COVID-19 patients treated with remdesivir plus dexamethasone (with or without baricitinib) on the day of hospital admission (I) \( (p < 0.0000001) \); (ii) between I and T (COVID-19 patients at 48 h post treatment) \( (p < 0.0000001) \); and (iii) between C and T \( (p = 0.001) \) (Figure 2A). ANOVA model and parameter estimates for the three groups of patients are presented in Table 3.
Surprisingly, it was determined that the antiviral plus dexamethasone treatment (with or without baricitinib)-induced sudden surge in the miR-6741-5p levels was detrimental to the subject (Figure 2B). We could accurately predict the LOS for the hospitalized patients within 48 h post treatment (Table 1). Our ANOVA results showed that there was a significant difference in circulatory miR-6741-5p levels between the patients that had good prognosis or a shorter LOS versus that died, had a poor prognosis, or a longer LOS ($p = 4.68 \times 10^{-16}$) (Figure 2B).

Our ANOVA model, as presented in Table 4, predicting good or poor prognosis in COVID-19 patients treated with remdesivir and dexamethasone (with or without baricitinib) on the day of hospital admission based on the circulatory miR-6741-5p expression levels are presented below (Equations (1) and (2)). The coefficient of determination (R squared) of the model was 0.997 (Table 4), suggestive of good model fit with sufficient predictive power. Parameters were estimated with robust standard errors using HC3 method. Our model estimated marginal mean of 12.42 for log2 CPM may serve as a “clinical threshold” between survival and death.

$$\text{Good prognosis} = 11.168 \text{ Log2 CPM} + 0.170$$ (2)

$$\text{Poor prognosis} = 13.675 \text{ Log2 CPM} + 0.130$$ (3)

### 3.3. miR-6741-5p Targets APOBEC3H

One miRNA may regulate multiple genes, while one gene may also be targeted by many miRNAs [25]. Accordingly, miR-6741-5p can possibly target several genes (Figure S3). Using bioinformatics tools (miRDB and TargetScan) [26,27], we proposed to test the top two promising targets to miR-6741-5p. The selection criteria for the two candidates were based on the target score [26] as well as the biological relevance of the target. The plausible binding site of miR-6741-5p is located in the 3′-UTR of HNRNPA1L2 and APOBEC3H mRNA (Figure S4). To confirm the ability of miR-6741-5p to specifically bind and interact with HNRNPA1L2 and APOBEC3H 3′-UTR regions, we used the conventional luciferase reporter assay. Transfection of HEK293T cells with miR-6741-5p mimic significantly lowered the luciferase activity of wild-type (WT) APOBEC3H 3′-UTR vector plasmid and not the vector encoding the WT-HNRNPA1L2 3′-UTR (Figure 3). In the conditions tested, miR-6741-5p mimic did not lower luciferase activity of the vector encoding the WT-HNRNPA1L2 3′-UTR and this could be due to one or more of the following reasons: (i) predictions based on genome-wide computation models may not necessarily result in functional target suppression [28,29]; (ii) limitations of the luciferase-based target validation [30]; and (iii) to the cell-type tested in this assay. Transfection of cells with miR-NC could specifically inhibit luciferase activity of wild-type (WT) APOBEC3H 3′-UTR vector plasmid (Figure 3). The specificity the miR-6741-5p interactions with APOBEC3H 3′-UTR region was confirmed by using MUT1 and MUT2 variants (Table S1): transfection of HEK293T cells with miR-6741-5p mimic significantly lowered the luciferase activity of MUT1 APOBEC3H 3′-UTR vector plasmid and not the MUT1 APOBEC3H 3′-UTR vector plasmid (Figure 3). Taken together, the results suggest a key role for target site located in 3′-UTR region of APOBEC3H (position 24–31; Figure S4) with which miR-6741-5p interacts.
We found PCA of plasma miRNA profiles could distinguish COVID-19 patients (group I) when they received remdesivir plus dexamethasone (with or without baricitinib) treatment and at 48 h post treatment (T). The difference in changes to miRNA profile within 48 h post treatment was assumed to be the net effect of antiviral plus dexamethasone with or without baricitinib treatment. PCA is used to identify strong patterns in large, complex data sets [32]. It is considered as the initial step in an exploratory analysis on expression data such as miRNA profiles [33]. This is widely used effectively to reduce a large set of variables into smaller, easier-to-analyze sets while retaining meaningful information [32]. We found PCA of plasma miRNA profiles could distinguish COVID-19 patients (group I) from healthy volunteers (group C). PCA analysis showed distinct clusters for group C and I (Figure 1A,C); whereas COVID-19 patients (group I) clustered relatively closer to COVID-19 patients treated for 48 h (group T) (Figure 1B). Such a cluster pattern between groups I and
T is partly because of the shorter time interval post treatment and the inherent variations in the host responses to the treatment. It is evident that the discriminating miRNAs, such as miR-6741-5p, that result from such an analysis may prove to be robust biomarkers.

Only nine circulatory miRNAs were differentially expressed between groups I and T compared to groups I and C, and groups T and C (Figure 1D–F). Of these, only miR-6741-5p was upregulated in COVID-19 patients that were treated (T) (Figure 2A). We were interested in the expression of miR-6741-5p for two reasons: (i) the significant difference in the expression levels of miR-6741-5p between the three groups of participants (Figure 2A); and (ii) the putative targets of miR-6741-5p and their possible relevance to COVID-19 biology (Figure 3).

There was a unique pattern of expression in COVID-19 patients who received treatment. SARS-CoV-2 infection as such lowers the expression of miR-6741-5p (Figure 2A). Upon treatment, in a subset of COVID-19 patients we observed a sudden spike in the miR-6741-5p expression (Figure 2B) and that was a sign of poor prognosis, or longer LOS (Table 1). The COVID-19 patients who survived post treatment generally had only a slight or no change in the expression of miR-6741-5p (Figure 2B). An estimated marginal mean of 12.42 for Log2 CPM (shown as dotted line in Figure 2B) may serve as a “clinical threshold” that may allow clinicians to determine who may survive (good prognosis) or die (poor prognosis) among COVID-19 patients. More specifically, all patients with below 12.42 Log2 CPM survived, had a short LOS, or a good prognosis (n = 7); whereas all patients with over 12.42 Log2 CPM died, had a long LOS, or a poor prognosis (n = 11). The LOS for all patients are shown in Table 1. Inflammatory biomarkers such as C-reactive protein (CRP), D-dimer, and ferritin are often elevated in COVID-19 patients [35]. We did not observe a significant correlation between the levels of inflammatory biomarkers during early times of treatment and the treatment outcome as suggested in earlier studies [24,36]. However, medical interventions such as mechanical ventilation and oxygenation seem to have a correlation with the prognosis of the disease. All the individuals who were on ventilation and/or received oxygen for an extended period of time had poor prognosis or died (Supplemental Table S2). The miR-6741-5p expression in plasma obtained from patients treated with remdesivir plus dexamethasone (with baricitinib) at 48 h post treatment was slightly higher than those treated without baricitinib (12.82 vs. 10.3 log2 CPM). This can be explained by the fact that there are still concerns that JAK inhibitors such as baricitinib may increase the incidence of COVID-19-associated pulmonary aspergillosis (CAPA) when used with corticosteroids [37].

In our recently concluded study [24], we did not mention miR-6741-5p as the discussion was only on the select miRNAs that were altered ≥10 folds due to SARS-CoV-2 infection. The effects of miR-6741-5p on COVID-19 biology could be multiple based on the potential target genes (Figure S3). The overall pleiotropic effects of a sudden increase in miR-6741-5p expression in COVID-19 patients seem to lower adaptive immunity, pro-inflammatory response, healing process, cell proliferation and survivability while increasing viral replication; all of which may result in a poor prognosis (Figure S5) [38–46]. It is important to note that the miR-6741-5p expression levels in those with poor prognosis are at comparable levels to what is observed in healthy individuals (Figure S6). This is a scientific paradox. Herein, we will attempt to solve the paradox using our working hypothetical model as follows: the biological effect of a miRNA is going to be different in a healthy individual compared to an individual who is responding to a viral infection; the biotic milieu is different (Figure 4). In a healthy naïve individual, an innate immune response is only triggered following an exposure to a pathogen and so there is not going to be an adaptive immune response [47]. The inflammatory responses and cell proliferation in a healthy individual are at adequate levels. When SARS-CoV-2 infects a person with a good prognosis, there is a decrease in the miR-6741-5p levels that promote an innate immune response followed by a robust specific adaptive immune response to fight the viral pathogen. There is an increase in pro-inflammatory response to combat virus-induced pathology and inflammation, followed by healing process (cell proliferation and surviv-
ability). In a subset of few patients where there is a sudden surge in the miR-6741-5p levels (comparable to healthy individuals), the net effect is different as they are affected with an ensuing virus-induced pathology. Such a sudden surge in miR-6741-5p leads to a decrease in adaptive viral specific immunity, pro-inflammatory response, antiviral response, cell proliferation and survivability; and thus a poor prognosis. In this study, we were also able to establish miR-6741-5p to physically bind, interact, and regulate expression of APOBEC3H gene (Figure 3). Human APOBEC3H has two major functions: DNA cytosine deaminase [48] and DNA editing enzymatic activity [49]. The gene ontology (GO) annotations for APOBEC3H are provided in Table S3. The DNA editing enzyme function of APOBEC3H plays a crucial role in innate and adaptive immune responses to viruses like herpesviruses, retroviruses, and potentially RNA viruses such as SARS-CoV-2 [39,42,50]. The APOBEC3H is regulated by interferons (another key mediator of innate immunity) [51] and thus may not have a direct bearing in healthy individuals when compared to infected patients. An integrated network and dynamical reasoning assembler (INDRA)-interactive pathway map (INDRA-IPM) [52] representing the ability APOBEC3H to negatively regulate viral genome is presented in Figure S7. In a recently concluded study, it was determined that the levels of APOBEC3H were higher in older individuals [53]. Controneo et al. [53] concluded the necessity to understand if APOBEC3H isoforms affect prognosis in older COVID-19 patients.

**Hypothetical model**

| Healthy (C) | COVID-19 Patients (I) | COVID-19 patients who received treatment for 48h |
|-------------|-----------------------|--------------------------------------------|
| miR-6741-5p (log, CPM) | 13.73 | 10.93 | 11.16 | 13.65 |
| miR-6741-5p trend | None | None | Oxygen (if needed) | Mechanical ventilation & Oxygenation for extended periods |
| Medical interventions | None | None | Decreased adaptive immunity |
| NET effect of miR-6741-5p* | Good innate response & adaptive immunity | Robust innate response & adaptive immunity | Robust innate response & adaptive immunity |

*Host response in these two groups may look identical. However, the holistic effects of the miR-6741-5p-induced environment yield different outcomes based on exposure to virus infection. A sudden surge in miR-6741-5p in COVID-19 infected patients results in a milieu that support poor prognosis.*

**Figure 4.** A schematic model describing the working hypothesis. * refer to Supplemental Figure S4.

5. Limitations

Besides the sample size, there are other limitations of this study. First, the samples were from patients hospitalized with COVID-19 in the summer of 2021. At that time, the Delta variant was the predominant strain of SARS-CoV-2 circulating in the US and in our hospital. Whether the same miRNAs are expressed with Omicron and other variants remain to be determined. We plan to investigate this thesis using plasma samples from patients hospitalized with COVID-19 this year when Omicron has been responsible for >95% of hospitalizations. Also, we do not know what effects, if any, other antivirals such as molnupiravir or nirmatrelvir/ritonavir might have on the miRNA profiles. Finally, all patients in this study presented at various times in the illness. As such, we do not have a clear picture of when the drop in the level of miR-6741-5p relative to infection
occurs. Despite these limitations, we are confident that this may serve as a steppingstone to understand the role of miR-6741-5p-regulated APOBEC3H in COVID-19 biology.

6. Conclusions

Based on the above available data, we propose a model (Figure 4) to explain the role of miR-6741-5p in COVID-19 biology post initiation of treatment. Each individual responds in a unique way to treatment. In healthy control participants (C), a basal level of miR-6741-5p is observed. SARS-CoV-2 infection results in a sharp decline in miR-6741-5p expression. A sharp decline in miR-6741-5p results in an upregulation of APOBEC3H-induced antiviral response. Such a virus-induced 10-fold APOBEC3H upregulation has been recorded in earlier studies [54]. Treatment of these COVID-19 patients results in two scenarios: (i) a sharp spike of miR-6741-5p; or (ii) a modest to no change in miR-6741-5p expression. A sharp spike in the miR-6741-5p expression results in a sudden depletion of APOBEC3H-induced antiviral activity that may support an increase in SARS-CoV-2-induced pathogenesis resulting in poor prognosis and vice versa. In sum, we show that circulatory miR-6741-5p may serve as a prognostic biomarker effectively predicting mortality risk and LOS of hospitalized COVID-19 patients.

Future studies are aimed at testing (i) our statistical model in a large sample population; and (ii) if miR-6741-5p expression can determine the prognosis at the time of admission. The APOBEC3H antiviral activity depends on recognition of RNA or DNA strand [55]. Accordingly, the direct target of APOBEC3H in the SARS-CoV-2 genome is underway.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/v14122681/s1: Supplementary Figure S1: Scree plots showing eigenvalues for the principal component presented in Figure 1. Supplementary Figure S2: Boxplots of the 8 miRNAs downregulated in COVID-19 patients with moderate-severe illness at 48 h post treatment. Supplemental Figure S3: Putative target genes for miR-6741-5p. Supplementary Figure S4: RNA hybrid analysis shows miR-6741-5p binding site in 3′-UTR of HNRNPA1L2 and APOBEC3H mRNA. Supplementary Table S1: Oligos used in the luciferase assay. Supplemental Figure S5: The net effect of a sudden surge of miR-6741-5p in the COVID-19 patients. Supplemental Figure S6: Statistical comparison of the miR-6741-5p expression in healthy volunteer group (C) compared to COVID-19 patients at 48h post treatment. Supplementary Table S2: Clinical biomarker levels during the course of treating COVID-19. Supplementary Table S3: GO Annotations for APOBEC3H. Supplemental Figure S7: Pathway map showing the negative regulation of viral genome by APOBEC3H.

Author Contributions: S.M.A. and P.P.C. designed the study. J.F.W., S.M.A., S.R. and P.P.C. performed experiments. A.N.B. did the pathway and gene ontology analysis. L.R.P. did the statistics. S.M.A. wrote the first draft of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported partly by grant from federal COVID-19 relief funds (appropriated to Brody School of Medicine and ECU in NC Session Law 2020-4) to SMA, PPC.

Institutional Review Board Statement: All protocols were approved by the University and Medical Center IRB (UMCIRB) review board (approved UMCIRB study number is UMCIRB 20-001604).

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are contained within the article or Supplementary Materials.

Acknowledgments: We thank John T. Fallon, Christian Miller, and other staff of the Department of Pathology at ECU to kindly provide us with appropriate human specimens.

Conflicts of Interest: No potential conflict of interest was reported by the author(s). Authors also declare that they have no competing financial, professional or any non-financial competing interests that might be perceived to influence the interpretation of data or presentation of information described in this manuscript.
References

1. Feng, W.; Zong, W.; Wang, F.; Ju, S. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review. *Mol. Cancer* 2020, 19, 100. [CrossRef] [PubMed]

2. Maher, M.C.; Bartha, I.; Weaver, S.; di Iulio, J.; Ferri, E.; Soriaga, L.; Lempp, F.A.; Hie, B.L.; Bryson, B.; Berger, B.; et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern. *Sci. Transl. Med.* 2022, 14, eabk3445. [CrossRef] [PubMed]

3. Passarelli, P.C.; Lopez, M.A.; Mastandrea Bonaviri, G.N.; Garcia-Godoy, F.; D’Addona, A. Taste and smell as chemosensory dysfunctions in COVID-19 infection. *Am. J. Dent.* 2020, 33, 135–137. [PubMed]

4. Meo, S.A.; Al howikani, A.M.; Al-Khlaifi, T.; Meo, I.M.; Halepoto, D.M.; Iqbal, M.; Usmani, A.M.; Hajjar, W.; Ahmed, N. Novel coronavirus 2019-nCoV: Prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. *Eur. Rev. Med. Pharmacol. Sci.* 2020, 24, 2012–2019. [PubMed]

5. Li, Y.C.; Bai, W.Z.; Hashikawa, T. The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients. *J. Med. Virol.* 2020, 92, 552–555. [CrossRef]

6. Yong, S.J. Long COVID or post-COVID-19 syndrome: Putative pathophysiology, risk factors, and treatments. *Infect. Dis. 2021*, 53, 737–754. [CrossRef]

7. Bellanti, J.A. The long COVID syndrome: A conundrum for the allergist/immunologist. *Allergy Asthma Proc.* 2012, 33, 368–374. [CrossRef]

8. Mumtaz, A.; Sheikh, A.A.E.; Khan, A.M.; Khalid, S.N.; Khan, J.; Nasrullah, A.; Sagheer, S.; Sheikh, A.B. COVID-19 Vaccine and Long COVID: A Scoping Review. *Life 2022*, 12, 1066. [CrossRef]

9. Raveendran, A.V.; Jayadevan, R.; Sashidharan, S. Long COVID: An overview. *Diabetes Metab. Syndr.* 2021, 15, 869–875. [CrossRef]

10. Sudre, C.H.; Murray, B.; Varsavsky, T.; Graham, M.S.; Penfold, R.S.; Bowyer, R.C.; Pujol, J.C.; Klaser, K.; Antonelli, M.; Canas, L.S.; et al. Attributes and predictors of long COVID. *Nat. Med.* 2021, 27, 626–631. [CrossRef]

11. Khetpal, V.; Berkowitz, J.; Vijayakumar, S.; Choudhary, M.; Mukand, J.A.; Rudolph, J.L.; Wu, W.C.; Erquoz, S. Long-term Cardiovascular Manifestations and Complications of COVID-19: Spectrum and Approach to Diagnosis and Management. *R. I. Med. J.* 2022, 105, 16–22.

12. Sommer, N.; Schmeck, B. Pulmonary manifestations in long COVID. *Inn. Med.* 2022, 63, 819–829.

13. Magdy, R.; Elmezny, A.; Basile, C.; Tuttle, K.; Kanbay, M. Post-acute COVID-19 syndrome and kidney diseases: What do we know? *J. Nephrol.* 2022, 35, 795–805. [CrossRef]

14. Zhu, M.; Chen, D.; Zhu, Y.; Xiong, X.; Ding, Y.; Guo, F.; Zhu, M.; Zhou, J. Long-term sero-positivity for IgG, sequelae of respiratory dysfunctions in COVID-19 infection. *Eur. Med.* 2021, 40, 1559–1567. [CrossRef]

15. Esteller, M. Non-coding RNAs in human disease. *Nat. Rev. Genet.* 2011, 12, 861–874. [CrossRef]

16. Adams, B.D.; Kasinski, A.L.; Slack, F.J. Aberrant regulation and function of microRNAs in cancer. *Curr. Biol.* 2014, 24, R762–R776. [CrossRef]

17. Kloosterman, W.P.; Plasterk, R.H. The diverse functions of microRNAs in animal development and disease. *Dev. Cell 2006*, 11, 441–450. [CrossRef]

18. Zhang, S.; Amahong, K.; Sun, X.; Lian, X.; Liu, J.; Sun, H.; Lou, Y.; Zhu, F.; Qiu, Y. The miRNA: A small but powerful RNA for COVID-19. *Brief. Bioinform.* 2021, 22, 1137–1149. [CrossRef]

19. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J. Biol. Chem.* 2010, 285, 17442–17452. [CrossRef] [PubMed]

20. Rees, E.M.; Nightingale, E.S.; Jafari, Y.; Waterlow, N.R.; Clifford, S.; CA, B.P.; Group, C.W.; Jombart, T.; Procter, S.R.; Knight, G.M. COVID-19 length of hospital stay: A systematic review and data synthesis. *BMC Med.* 2020, 18, 270. [CrossRef] [PubMed]

21. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J. Biol. Chem.* 2010, 285, 17442–17452. [CrossRef] [PubMed]

22. Elsayed, R.M.; et al. Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: A case-control study. *J. Headache Pain* 2020, 21, 18. [CrossRef]

23. Sommer, N.; Schmeck, B. Pulmonary manifestations in long COVID. *Inn. Med.* 2022, 63, 819–829.

24. Magdy, R.; Elmezny, A.; Basile, C.; Tuttle, K.; Kanbay, M. Post-acute COVID-19 syndrome and kidney diseases: What do we know? *J. Nephrol.* 2022, 35, 795–805. [CrossRef]

25. Zhu, M.; Chen, D.; Zhu, Y.; Xiong, X.; Ding, Y.; Guo, F.; Zhu, M.; Zhou, J. Long-term sero-positivity for IgG, sequelae of respiratory symptoms, and abundance of malformed sperms in a patient recovered from severe COVID-19. *Eur. J. Clin. Microbiol. Infect. Dis.* 2021, 40, 1559–1567. [CrossRef]

26. Esteller, M. Non-coding RNAs in human disease. *Nat. Rev. Genet.* 2011, 12, 861–874. [CrossRef]

27. Adams, B.D.; Kasinski, A.L.; Slack, F.J. Aberrant regulation and function of microRNAs in cancer. *Curr. Biol.* 2014, 24, R762–R776. [CrossRef]

28. Kloosterman, W.P.; Plasterk, R.H. The diverse functions of microRNAs in animal development and disease. *Dev. Cell 2006*, 11, 441–450. [CrossRef]

29. Zhang, S.; Amahong, K.; Sun, X.; Lian, X.; Liu, J.; Sun, H.; Lou, Y.; Zhu, F.; Qiu, Y. The miRNA: A small but powerful RNA for COVID-19. *Brief. Bioinform.* 2021, 22, 1137–1149. [CrossRef]

30. Kosaka, N.; Iguchi, H.; Yoshioka, Y.; Takeshita, F.; Matsuki, Y.; Ochiya, T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J. Biol. Chem.* 2010, 285, 17442–17452. [CrossRef] [PubMed]

31. Rees, E.M.; Nightingale, E.S.; Jafari, Y.; Waterlow, N.R.; Clifford, S.; CA, B.P.; Group, C.W.; Jombart, T.; Procter, S.R.; Knight, G.M. COVID-19 length of hospital stay: A systematic review and data synthesis. *BMC Med.* 2020, 18, 270. [CrossRef] [PubMed]

32. Huang, N.; Lee, K.J.; Stark, M.S. Current Trends in Circulating Biomarkers for Melanoma Detection. *Front. Med.* 2022, 9, 873728. [CrossRef] [PubMed]

33. Akula, S.; Bolin, P.; Cook, P.P. Cellular miR-150-5p may have a crucial role to play in the biology of SARS-CoV-2 infection by regulating nsf10 gene. *RNA Biol.* 2022, 19, 1–11. [CrossRef]

34. Hashimoto, Y.; Akiyama, Y.; Yuasa, Y. Multiple-to-multiple relationships between microRNAs and target genes in gastric cancer. *PloS ONE 2013*, 8, e65289. [CrossRef]

35. Agarwal, V.; Bell, G.W.; Nam, J.W.; Bartel, D.P. Predicting effective microRNA target sites in mammalian mRNAs. *Elife 2015*, 4, e05005. [CrossRef]

36. Chen, Y.; Wang, X. miRDB: An online database for prediction of functional microRNA targets. *Nucleic Acids Res.* 2020, 48, D127–D131. [CrossRef]

37. Liu, W.; Wang, X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. *Genome Biol.* 2019, 20, 18. [CrossRef]
29. Betel, D.; Koppal, A.; Agius, P.; Sander, C.; Leslie, C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 2010, 11, R90. [CrossRef]

30. Kuhn, D.E.; Martin, M.M.; Feldman, D.S.; Terry, A.V., Jr.; Nuovo, G.J.; Elton, T.S. Experimental validation of miRNA targets. Methods 2008, 44, 47–54. [CrossRef]

31. Gustafson, D.; Ngai, M.; Wu, R.; Hou, H.; Schoffel, A.C.; Erice, C.; Mandla, S.; Billia, F.; Wilson, M.D.; Radisic, M.; et al. Cardiovascular signatures of COVID-19 predict mortality and identify barrier stabilizing therapies. EBioMedicine 2022, 78, 103982. [CrossRef]

32. Sell, S.L.; Widen, S.G.; Prough, D.S.; Hellmich, H.L. Principal component analysis of blood microRNA datasets facilitates diagnosis of diverse diseases. PLoS ONE 2020, 15, e0234185. [CrossRef]

33. Jolliffe, I.T.; Cadima, J. Principal component analysis: A review and recent developments. Philos. Trans. A Math Phys. Eng. Sci. 2016, 374, 20150202. [CrossRef]

34. Guerra-Urzola, R.; Van Deun, K.; Vera, J.C.; Sijsitsma, K. A Guide for Sparse PCA: Model Comparison and Applications. Psychometrika 2021, 86, 893–919. [CrossRef]

35. Huang, I.; Pranata, R.; Lim, M.A.; Oehadian, A.; Alisjahbana, B. C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: A meta-analysis. Ther. Adv. Respir. Dis. 2020, 14, 1–14. [CrossRef]

36. Barrett, B.; Pamphile, S.; Yang, F.; Naeem, F.; Kim, J.; Annam, J.; Borczuk, R.; Yellin, S.; Bass, C.; Fowler, S.; et al. Inflammatory markers are poorly predictive of clinical outcomes among hospitalized patients with COVID-19. Am. J. Emerg. Med. 2020, 46, 595–598. [CrossRef]

37. Shimada, I.; Ohnaka, S.; Kubo, K.; Nakashima, M.; Nagai, A. COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated with Remdesivir, Dexamethasone, and Baricitinib: A Case Report. Curahea 2022, 14, e23755. [CrossRef]

38. Jiang, G.; Gong, M.; Song, H.; Sun, W.; Zhao, W.; Wang, L. Tob2 Inhibits TLR-Induced Inflammatory Responses by Association with TRAF6 and MyD88. J. Immunol. 2020, 205, 981–986. [CrossRef]

39. Leonard, B.; Starrett, G.J.; Maurer, M.J.; Oberg, A.L.; Van Bockstal, M.; Van Dorpe, J.; De Wever, O.; Helleman, J.; Sieuwerts, A.M.; Berns, E.M.; et al. APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma. Clin. Cancer Res. 2016, 22, 4746–4755. [CrossRef]

40. Liu, D.; Zhou, G.; Shi, H.; Chen, B.; Sun, X.; Zhang, X. Downregulation of Transmembrane protein 40 by miR-138-5p Suppresses Cell Proliferation and Mobility in Clear Cell Renal Cell Carcinoma. Iran J. Biotechnol. 2020, 18, e2270.

41. Mazzocca, A.; Carloni, V.; Sciamaetta, S.; Cordella, C.; Pantaleo, P.; Caldini, A.; Gentilini, P.; Pinzani, M. Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. J. Hepatol. 2002, 37, 322–330. [CrossRef] [PubMed]

42. Meissner, M.E.; Willkomm, N.A.; Lucas, J.; Arndt, W.G.; Aitken, S.F.; Julik, E.J.; Baliga, S.; Mansky, L.M. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2. J. Mol. Biol. 2022, 434, 167355. [CrossRef] [PubMed]

43. Mondal, A.; Appu, A.P.; Sadhukhan, T.; Bagh, M.B.; Previde, R.M.; Sadhukhan, S.; Stojilkovic, S.; Liu, A.; Mukherjee, A.B. Ptp1-deficiency dysregulates lysosomal Ca (++) homeostasis contributing to pathogenesis in a mouse model of CLN1 disease. J. Inherit. Metab. Dis. 2022, 45, 635–656. [CrossRef] [PubMed]

44. Nair, S.; Bora-Singhal, N.; Perumal, D.; Chellappan, S. Nicotine-mediated invasion and migration of non-small cell lung carcinoma cells by modulating STMNS3 and GSPIT1 genes in an ID1-dependent manner. Mol. Cancer 2014, 13, 173. [CrossRef]

45. Tartey, S.; Gurung, P.; Dasari, T.K.; Burton, A.; Kanneganti, T.D. ASK1/2 signaling promotes inflammation in a mouse model of neutrophilic dermatosis. J. Clin. Investig. 2018, 128, 2042–2047. [CrossRef]

46. Yu, L.; Liu, J.; Zhang, T.D.; Zheng, X.F.; Luo, D.L.; Zhu, W.L.; Qiu, X.W.; Guo, L.L. Decreased TMEM40 expression is associated with malignant behavior of cutaneous squamous cell carcinoma and inhibits tumor progression. Oncol. Lett. 2021, 22, 606. [CrossRef]

47. Alberts, B.; Hunt, T.; Johnson, A.; Lewis, J.; Morgan, D.; Raff, M.C.; Roberts, K.; Walter, P.; Wilson, J.; Alberts, B.; et al. Molecular Biology of the Cell, 6th ed.; Garland Science, Taylor and Francis Group: New York, NY, USA, 2015; p. xxxiv, 1342, 34, 53, 1 pages: Illustrations (chiefly color).

48. Conticello, S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008, 9, 229. [CrossRef]

49. Shaban, N.M.; Shi, K.; Lauer, K.V.; Carpenter, M.A.; Richards, C.M.; Salamango, D.; Wang, J.; Lopresti, M.W.; Banerjee, S.; Levin-Klein, R.; et al. The Antiviral and Cancer Genomic DNA Deaminase APOBEC3H Is Regulated by an RNA-Mediated Dimerization Mechanism. Mol. Cell 2018, 69, 75–86. [CrossRef]

50. Ratcliff, J.; Simmonds, P. Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution. Virology 2021, 556, 62–72. [CrossRef]

51. Tan, L.; Sarkis, P.T.; Wang, T.; Tian, C.; Yu, X.F. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1. FASEB J. 2009, 23, 279–287. [CrossRef]

52. Todorov, P.V.; Gyori, B.M.; Bachman, J.A.; Sorger, P.K. INDRA-IPM: Interactive pathway modeling using natural language with automated assembly. Bioinformatics 2019, 35, 4501–4503. [CrossRef]
53. Cotroneo, C.E.; Mangano, N.; Dragani, T.A.; Colombo, F. Lung expression of genes putatively involved in SARS-CoV-2 infection is modulated in cis by germline variants. *Eur. J. Hum. Genet.* **2021**, *29*, 1019–1026. [CrossRef]

54. Refsland, E.W.; Hultquist, J.F.; Luengas, E.M.; Ikeda, T.; Shaban, N.M.; Law, E.K.; Brown, W.L.; Reilly, C.; Emerman, M.; Harris, R.S. Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. *PLoS Genet.* **2014**, *10*, e1004761. [CrossRef]

55. Bohn, J.A.; DaSilva, J.; Kharytonchyk, S.; Mercedes, M.; Vosters, J.; Telesnitsky, A.; Hatzioannou, T.; Smith, J.L. Flexibility in Nucleic Acid Binding Is Central to APOBEC3H Antiviral Activity. *J. Virol.* **2019**, *93*, e01275-19. [CrossRef]